SIR -Recently, three studies reported genetic association of an anonymous microsatellite marker on chromosome 10p12 (D10S1423) and Alzheimer's disease (AD), [1] [2] [3] whereas a fourth study failed to replicate these findings 4 . At least four linkage studies have implicated regions on chromosome 10 as likely to harbor an AD susceptibility gene [5] [6] [7] [8] ; however, all reported linkage peaks map considerably distal to D10S1423 (440 cM). In an attempt to clarify these conflicting results, we have tested D10S1423 as well as two adjacent markers (D10S2325 and D10S1426) for association with AD in a large and well characterized sample of multiplex AD families using familybased methodologies. Our results show no evidence of association between any of these markers and disease phenotype, neither in the sample as a whole nor in subsamples stratified by APOE e4-genotype or onset age. These negative findings are consistent with linkage analyses performed on the same sample 5 and also with other independent linkage studies, [6] [7] [8] suggesting that the putative chromosome 10 AD gene(s) is located considerably further distal (q-ter).
AD is a genetically complex and heterogeneous disorder in the sense that several genetic as well as nongenetic risk factors are believed to modify disease risk and/or onset age. 9 Despite intensive research by a large number of laboratories worldwide, only one genetic risk factor has been established for the most common, late-onset form of the disease: the e4-allele of the gene encoding apolipoprotein E (APOE) on chromosome 19. 10 Although several lines of evidence suggest the existence of additional genetic risk factors, none of the association findings between AD and more than three dozen genes has been consistently replicated in independent follow-up analyses. 9 The association described for marker D10S1423 is remarkable because three independent studies provided evidence of association between one of its alleles ('234 bp') and AD, but there is no evidence for genetic linkage in the corresponding chromosomal region (10p12) in any of the published full genome screens and this marker is not near any known mapped genes.
10 Furthermore, the experiment-wide significance levels in at least two of the positive studies were only marginal, 1, 3 and the association was only evident when controlling for the presence of APOE e4 in the third study. 2 Finally, the fourth analysis, with the greatest number of cases, failed to replicate these findings altogether. 4 Of note, several research groups using varying samples and various methods of linkage and/or association analysis [5] [6] [7] [8] 11 have implicated chromosome 10 as harboring a novel AD locus. However, only one of these studies has reported a signal on the short arm of chromosome 10, 11 whereas all other reports localize the putative AD gene on chromosome 10 at least 40-90 Mb downstream towards the long arm.
In this study, we analyzed the largest single AD family sample collected to date; the National Institute of Mental Health (NIMH) Genetics Initiative AD study sample. Recruitment procedures and sample characteristics have been described elsewhere. 12 Briefly, the NIMH sample consists of 437 families with at least two sampled affected individuals, with all sampled affecteds experiencing disease onset beyond age 50 years (n ¼ 1439 subjects: 993 affected [mean age of onset 72.477.7 years], 411 unaffected, 37 with unknown phenotypes). Thus far, a clinical diagnosis of AD has been confirmed in 94% of the 326 cases that came to autopsy. To assess association/linkage disequilibrium in the region, three microsatellite markers were tested in the B20 Mb interval around D10S1423 (Table 1) . Marker genotypes were provided by the Center for Inherited Disease Research (CIDR) and genotyping protocols can be found on the CIDR website at: http://www.cidr.jhmi.edu. To test for association we used EV-FBAT 13, 14 under an additive disease model as described previously. 15 Like the transmission-disequilibrium test (TDT) and other family-based association tests, this method is not susceptible to bias due to population admixture. Applying this test, none of the markers yielded evidence of association using either the multiallelic (Table 2) or biallelic mode (data available from the authors upon request) in any of the tested strata. In particular, no association was observed with the 234 bp allele of D10S1423 and AD phenotype, contrary to previous case-control reports (total sample: Z ¼ 0.5, P ¼ 0.62, and APOE e4-positive: Z ¼ À0.1, P ¼ 0.92). In comparison, testing the polymorphisms at APOE in the same sample we clearly observe the established association between this gene and AD (e4: Z ¼ 5.4, Po1 Â 10 À6 , and e2: Z ¼ À4.1, P ¼ 0.000048). To our knowledge, this is not only the largest study to date, investigating -and refuting -the potential association of genetic markers around chromosome 10p12 and AD, but also the first report to employ family-based methodologies. Independent replication or refutation of putative disease associations is crucial in elucidating the genetic makeup of any complex disease. The discrepancy between this and the previous positive studies could be due to the effect of one or -more likely -several factors that generally aggravate the identification of genes in complex diseases like AD: (1) Locus and/or allelic heterogeneity, that is, one or more loci and/or alleles are contributing to disease risk in any given population; (2) only minor to modest effect of associated genetic variants, making replication of marginally significant findings difficult; (3) unknown -and difficult to model -interaction patterns among genes and/or environmental factors; (4) population differences and stratification (or 'admixture'), which is a potential problem in case-control, but not in familybased association studies; and 5) inadequate sample sizes and/or sampling strategies. 16 Although the first three of these factors are fundamental to the disease itself, the latter two can be addressed to a substantial extent through the analysis of larger samples and the employment of family-based association methods, as was done in our study. In addition-and as was pointed out in recent recommendations on the design of complex disease association studies 17, 18 -it is crucial to adjust results for multiple comparisons and, if possible, provide supportive evidence from linkage and functional studies. In particular, the latter two criteria are not fulfilled with respect to the role of D10S1423 in AD. This supports our overall conclusion that -if not altogether spurious -the association observed around chromosome 10p12 in previous studies is unlikely to contribute significantly to the overall risk of developing AD. Indeed, judging from our results here and from the currently available data in the literature, the putative and as yet elusive chromosome 10 AD gene is probably located several tens of million base-pairs further downstream. 
